Title |
Agomelatine: The evidence for its place in the treatment of depression
|
---|---|
Published in |
Core Evidence, August 2009
|
DOI | 10.2147/ce.s6005 |
Pubmed ID | |
Authors |
Daniela Eser, Thomas C Baghai, Hans-Jürgen Möller |
Abstract |
Depressive disorders are among the main causes of disability due to disease. In spite of recent progress in the pharmacotherapy of depression, there is still a high nonresponse rate of approximately 30% to the first antidepressant treatment. Furthermore, the latency of several weeks until sufficient clinical improvement and the risk of side effects remain unresolved problems. Therefore, there is still further need for the development of new antidepressants. In the last years a variety of melatonin receptor agonists have been synthesized and evaluated for the treatment of sleep disorders. Animal studies suggested that agomelatine (S-20098), a synthetic melatonergic MT(1) and MT(2) receptor agonist with serotonin receptor antagonistic properties, may have additional activating properties and may represent a new approach in the treatment of depression. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 2% |
Germany | 1 | 2% |
Unknown | 61 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 14 | 22% |
Student > Master | 6 | 10% |
Professor | 6 | 10% |
Student > Ph. D. Student | 5 | 8% |
Student > Bachelor | 4 | 6% |
Other | 12 | 19% |
Unknown | 16 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 20 | 32% |
Agricultural and Biological Sciences | 7 | 11% |
Psychology | 5 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
Neuroscience | 3 | 5% |
Other | 6 | 10% |
Unknown | 18 | 29% |